Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Current progress in CAR-T cell therapy for tumor treatment

The development of CAR design for tumor CAR-T cell therapy